Valneva SE (NASDAQ:VALN - Free Report) - Research analysts at HC Wainwright dropped their FY2024 EPS estimates for shares of Valneva in a research report issued on Thursday, January 23rd. HC Wainwright analyst E. White now expects that the company will post earnings per share of $0.13 for the year, down from their prior forecast of $0.15. HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Valneva's current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva's FY2025 earnings at ($1.29) EPS and FY2026 earnings at ($1.17) EPS.
Valneva Stock Performance
NASDAQ:VALN traded down $0.11 during midday trading on Monday, reaching $4.79. The stock had a trading volume of 17,361 shares, compared to its average volume of 42,971. The firm has a fifty day simple moving average of $4.29 and a two-hundred day simple moving average of $5.76. Valneva has a 12-month low of $3.62 and a 12-month high of $9.50. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70. The stock has a market cap of $389.24 million, a P/E ratio of -36.85 and a beta of 1.93.
Institutional Investors Weigh In On Valneva
A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC lifted its position in shares of Valneva SE (NASDAQ:VALN - Free Report) by 33.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 118,000 shares of the company's stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned approximately 0.15% of Valneva worth $717,000 at the end of the most recent quarter. 11.39% of the stock is owned by institutional investors and hedge funds.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
